# Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.

> **NCT00101686** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 547 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Modified Bolus 5-FU/LV with Irinotecan
- **DRUG:** FOLFIRI + bevacizumab
- **DRUG:** miFL + bevacizumab
- **DRUG:** Infusional 5-FU/LV with Irinotecan
- **DRUG:** Oral Capecitabine with Irinotecan

## Key facts

- **NCT ID:** NCT00101686
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 547 (ACTUAL)
- **Last updated:** 2010-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00101686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00101686, "Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00101686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*